Skip to main content
Top
Published in: Current Allergy and Asthma Reports 3/2017

01-03-2017 | Asthma (WJ Calhoun and V Ortega, Section Editors)

The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract

Authors: Malgorzata Pawełczyk, Marek Leszek Kowalski

Published in: Current Allergy and Asthma Reports | Issue 3/2017

Login to get access

Abstract

Viral infections are leading causes of both upper and lower airway acute illness in all age groups of healthy persons, and have also been implicated in the acute exacerbations of chronic respiratory disorders like asthma and COPD. Human rhinovirus, respiratory syncytial virus, influenza virus and coronavirus have been considered as the most important respiratory pathogens and relatively little attention has been paid to the role of parainfluenza viruses (hPIVs). Human parainfluenza viruses are single-stranded RNA viruses belonging to the paramyxovirus family that may evoke lower respiratory infections in infants, children and immunocompromised individuals. Among non-immune compromised adults, hPIV infection typically causes mild disease manifested as upper respiratory tract symptoms and is infrequently associated with severe croup or pneumonia. Moreover, hPIV infection may be associated with viral exacerbations of chronic airway diseases, asthma or COPD or chronic rhinosinusitis. In this review, we summarized the basic epidemiology and immunology of hPIVs and addressed the more recent data implicating the role of parainfluenza viruses in the exacerbation of chronic airway disorders.
Literature
2.
go back to reference Berman S. Epidemiology of acute respiratory infections in children of developing countries. Rev Infect Dis. 1991;(Suppl 6):S454–62. Berman S. Epidemiology of acute respiratory infections in children of developing countries. Rev Infect Dis. 1991;(Suppl 6):S454–62.
3.
go back to reference Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283(4):499–505.CrossRefPubMed Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000;283(4):499–505.CrossRefPubMed
4.
go back to reference Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—a GA2 LEN-DARE systematic review. Allergy. 2011;66(4):458–68.CrossRefPubMed Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma exacerbations—a GA2 LEN-DARE systematic review. Allergy. 2011;66(4):458–68.CrossRefPubMed
5.
go back to reference Reed G, Jewett PH, Thompson J, et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 year old. The Journal of Infectious Diseases. 1997;175:807–13.CrossRefPubMed Reed G, Jewett PH, Thompson J, et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 year old. The Journal of Infectious Diseases. 1997;175:807–13.CrossRefPubMed
6.
go back to reference Lee MS, Walker RE, Mendelman PM. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials. Hum Vaccin. 2005;1(1):6–11.CrossRefPubMed Lee MS, Walker RE, Mendelman PM. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials. Hum Vaccin. 2005;1(1):6–11.CrossRefPubMed
7.
go back to reference Tsukagoshi H, Ishioka T, Noda M, et al. Molecular epidemiology of respiratory viruses in virus-induced asthma. Front Microbiol. 2013;4:1–10.CrossRef Tsukagoshi H, Ishioka T, Noda M, et al. Molecular epidemiology of respiratory viruses in virus-induced asthma. Front Microbiol. 2013;4:1–10.CrossRef
8.
go back to reference Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990–2004. Clin Infect Dis. 2006;43:1016–22.CrossRefPubMed Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990–2004. Clin Infect Dis. 2006;43:1016–22.CrossRefPubMed
9.
go back to reference Laurichesse H, Dedman D, Watson JM, et al. Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997. Eur J Epidemiol. 1999;15(5):475–84.CrossRefPubMed Laurichesse H, Dedman D, Watson JM, et al. Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997. Eur J Epidemiol. 1999;15(5):475–84.CrossRefPubMed
10.
go back to reference Frost HM, Robinson CC. Dominguez epidemiology and clinical presentation of parainfluenza type 4 in children: a 3-year comparative study to parainfluenza types 1–3. JID. 2014;209:695–702.CrossRefPubMed Frost HM, Robinson CC. Dominguez epidemiology and clinical presentation of parainfluenza type 4 in children: a 3-year comparative study to parainfluenza types 1–3. JID. 2014;209:695–702.CrossRefPubMed
12.
go back to reference Kolakofsky D, Pelet T, Garcin D, et al. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol. 1998;72(2):891–9.PubMedPubMedCentral Kolakofsky D, Pelet T, Garcin D, et al. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol. 1998;72(2):891–9.PubMedPubMedCentral
13.
go back to reference Xu R, Palmer SG, Porotto M, et al. Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo. MBio. 2013;4(5):e00803–13.CrossRefPubMedPubMedCentral Xu R, Palmer SG, Porotto M, et al. Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo. MBio. 2013;4(5):e00803–13.CrossRefPubMedPubMedCentral
15.
go back to reference Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. 2009;7(7):e1000155.CrossRefPubMedPubMedCentral Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. 2009;7(7):e1000155.CrossRefPubMedPubMedCentral
16.
go back to reference • Schaap-Nutt A, Liesman R, Bartlett EJ, et al. Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium. Virology. 2012;433(2):320–8. Comparison of replication kinetics and cytokine release by different hPIV serotypes and description of serotype-specific clinical manifestation of infections.CrossRefPubMedPubMedCentral • Schaap-Nutt A, Liesman R, Bartlett EJ, et al. Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium. Virology. 2012;433(2):320–8. Comparison of replication kinetics and cytokine release by different hPIV serotypes and description of serotype-specific clinical manifestation of infections.CrossRefPubMedPubMedCentral
17.
go back to reference Gao J, Choudhary S, Banerjee AK, et al. Human parainfluenza virus type 3 upregulates ICAM-1 (CD54) expression in a cytokine-independent manner. Gene Expr. 2000;9(3):115–21.CrossRefPubMed Gao J, Choudhary S, Banerjee AK, et al. Human parainfluenza virus type 3 upregulates ICAM-1 (CD54) expression in a cytokine-independent manner. Gene Expr. 2000;9(3):115–21.CrossRefPubMed
18.
go back to reference •• Lewandowska-Polak A, Brauncajs M, Paradowska E, et al. Human parainfluenza virus type 3 (HPIV3) induces production of IFNγ and RANTES in human nasal epithelial cells (HNECs). J Inflamm. 2015;12:16. hPIV-3 infection of human airway epithelial cell line may induce expression and release of interferon gamma, which may contribute to local antiviral defense.CrossRef •• Lewandowska-Polak A, Brauncajs M, Paradowska E, et al. Human parainfluenza virus type 3 (HPIV3) induces production of IFNγ and RANTES in human nasal epithelial cells (HNECs). J Inflamm. 2015;12:16. hPIV-3 infection of human airway epithelial cell line may induce expression and release of interferon gamma, which may contribute to local antiviral defense.CrossRef
19.
go back to reference •• Yoshizumi M, Kimura H, Okayama Y, et al. Relationships between cytokine profiles and signaling pathways (IκB kinase and p 38 MAPK) in parainfluenza virus-infected lung fibroblasts. Front Microbiol. 2010;1:1–7. hPIV-induced generation of several proinflammatory (IL-1β, IL-6, TNF-α) and tissue remodeling-related cytokines (PDGF and VEGF) has been suggested to contribute to the prolonged airway inflammation and airway structural changes typical of asthma.CrossRef •• Yoshizumi M, Kimura H, Okayama Y, et al. Relationships between cytokine profiles and signaling pathways (IκB kinase and p 38 MAPK) in parainfluenza virus-infected lung fibroblasts. Front Microbiol. 2010;1:1–7. hPIV-induced generation of several proinflammatory (IL-1β, IL-6, TNF-α) and tissue remodeling-related cytokines (PDGF and VEGF) has been suggested to contribute to the prolonged airway inflammation and airway structural changes typical of asthma.CrossRef
20.
go back to reference Omenaas E, Bakke P, Haukenes G, et al. Respiratory virus antibodies in adults of a Norwegian community: prevalences and risk factors. Int J Epidemiol. 1995;24(1):223–31.CrossRefPubMed Omenaas E, Bakke P, Haukenes G, et al. Respiratory virus antibodies in adults of a Norwegian community: prevalences and risk factors. Int J Epidemiol. 1995;24(1):223–31.CrossRefPubMed
21.
go back to reference Sieg S, Muro-Cacho C, Robertson S, et al. Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3. Proc Natl Acad Sci U S A. 1994;91(14):6293–7.CrossRefPubMedPubMedCentral Sieg S, Muro-Cacho C, Robertson S, et al. Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3. Proc Natl Acad Sci U S A. 1994;91(14):6293–7.CrossRefPubMedPubMedCentral
22.
go back to reference Sieg S, King C, Huang Y, et al. The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. J Virol. 1996;70(7):4845–8.PubMedPubMedCentral Sieg S, King C, Huang Y, et al. The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3. J Virol. 1996;70(7):4845–8.PubMedPubMedCentral
23.
go back to reference Parisien JP, Bamming D, Komuro A, et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J Virol. 2009;83(14):7252–60.CrossRefPubMedPubMedCentral Parisien JP, Bamming D, Komuro A, et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J Virol. 2009;83(14):7252–60.CrossRefPubMedPubMedCentral
24.
go back to reference Lu LL, Puri M, Horvath CM, et al. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappa B kinase epsilon (IKKe)/TBK1. J Biol Chem. 2008;283(21):14269–76.CrossRefPubMedPubMedCentral Lu LL, Puri M, Horvath CM, et al. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappa B kinase epsilon (IKKe)/TBK1. J Biol Chem. 2008;283(21):14269–76.CrossRefPubMedPubMedCentral
25.
go back to reference Nishio M, Tsurudome M, Ito M, et al. Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect. J Virol. 2005;79(23):14756–68.CrossRefPubMedPubMedCentral Nishio M, Tsurudome M, Ito M, et al. Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect. J Virol. 2005;79(23):14756–68.CrossRefPubMedPubMedCentral
26.
go back to reference Schomacker H, Hebner RM, Boonyaratanakornkit J, et al. The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining stat 1 in perinuclear aggregates at the late endosome. PLoS One. 2012;7(2):e28382.CrossRefPubMedPubMedCentral Schomacker H, Hebner RM, Boonyaratanakornkit J, et al. The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining stat 1 in perinuclear aggregates at the late endosome. PLoS One. 2012;7(2):e28382.CrossRefPubMedPubMedCentral
27.
go back to reference Tyrrell DA, Bynoe ML. Studies on parainfluenza type 2 and 4 viruses obtained from patients with common colds. Br Med J. 19691:471–4. Tyrrell DA, Bynoe ML. Studies on parainfluenza type 2 and 4 viruses obtained from patients with common colds. Br Med J. 19691:471–4.
28.
29.
go back to reference Marx A, Torok TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis. 1997;176:1423–7.CrossRefPubMed Marx A, Torok TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis. 1997;176:1423–7.CrossRefPubMed
30.
go back to reference Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5):1681–8.CrossRefPubMedPubMedCentral Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5):1681–8.CrossRefPubMedPubMedCentral
31.
go back to reference Moscona A, Peluso RW. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion. J Virol. 1991;65(6):2773–7.PubMedPubMedCentral Moscona A, Peluso RW. Fusion properties of cells persistently infected with human parainfluenza virus type 3: participation of hemagglutinin-neuraminidase in membrane fusion. J Virol. 1991;65(6):2773–7.PubMedPubMedCentral
32.
go back to reference Ah-Tye C, Schwartz S, Huberman K, et al. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3. Microb Pathog. 1999;27(5):329–36.CrossRefPubMed Ah-Tye C, Schwartz S, Huberman K, et al. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3. Microb Pathog. 1999;27(5):329–36.CrossRefPubMed
33.
go back to reference Ruotsalainen M, Hyvärinen MK, Piippo-Savolainen E, et al. Adolescent asthma after rhinovirus and respiratory syncytial virus bronchiolitis. Pediatr Pulmonol. 2013;48(7):633–9.CrossRefPubMed Ruotsalainen M, Hyvärinen MK, Piippo-Savolainen E, et al. Adolescent asthma after rhinovirus and respiratory syncytial virus bronchiolitis. Pediatr Pulmonol. 2013;48(7):633–9.CrossRefPubMed
34.
go back to reference • Holtzman MJ, Shornick LP, Grayson MH, et al. “Hit-and-run” effects of paramyxoviruses as a basis for chronic respiratory disease. Pediatr Infect Dis J. 2004;23(11 Suppl):S235–45. New concept for asthma pathogenesis that includes epithelial, viral and allergic components and proposes viral reprogramming of the host immune response.CrossRefPubMed • Holtzman MJ, Shornick LP, Grayson MH, et al. “Hit-and-run” effects of paramyxoviruses as a basis for chronic respiratory disease. Pediatr Infect Dis J. 2004;23(11 Suppl):S235–45. New concept for asthma pathogenesis that includes epithelial, viral and allergic components and proposes viral reprogramming of the host immune response.CrossRefPubMed
35.
go back to reference Henrickson KJ, Savatski LL. Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1. J Infect Dis. 1997;176:867–75.CrossRefPubMed Henrickson KJ, Savatski LL. Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1. J Infect Dis. 1997;176:867–75.CrossRefPubMed
36.
go back to reference Azevedo AM, Durigon EL, Okasima V, et al. Detection of influenza, parainfluenza, adenovirus and respiratory syncytial virus during asthma attacks in children older than 2 years old. Allergol Immunopathol. 2003;31:311–7.CrossRef Azevedo AM, Durigon EL, Okasima V, et al. Detection of influenza, parainfluenza, adenovirus and respiratory syncytial virus during asthma attacks in children older than 2 years old. Allergol Immunopathol. 2003;31:311–7.CrossRef
38.
go back to reference Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310(6989):1225–9.CrossRefPubMedPubMedCentral Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310(6989):1225–9.CrossRefPubMedPubMedCentral
39.
go back to reference Matsuse H, Kondo Y, Saeki S, et al. Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotriens. Int Arch Allergy Immunol. 2005;138:267–72.CrossRefPubMed Matsuse H, Kondo Y, Saeki S, et al. Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotriens. Int Arch Allergy Immunol. 2005;138:267–72.CrossRefPubMed
40.
go back to reference Kwon JM, Shim JW, Kim DS, et al. Prevalence of respiratory viral infection in children hospitalized for acute lower respiratory tract diseases, and association of rhinovirus and influenza virus with asthma exacerbations. Korean J Pediatr. 2014;57(1):29–34.CrossRefPubMedPubMedCentral Kwon JM, Shim JW, Kim DS, et al. Prevalence of respiratory viral infection in children hospitalized for acute lower respiratory tract diseases, and association of rhinovirus and influenza virus with asthma exacerbations. Korean J Pediatr. 2014;57(1):29–34.CrossRefPubMedPubMedCentral
41.
go back to reference Lee MS, Greenberg DP, Yeh SH, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis. 2001;184:909–13.CrossRefPubMed Lee MS, Greenberg DP, Yeh SH, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis. 2001;184:909–13.CrossRefPubMed
42.
go back to reference Marx A, Gary Jr HE, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis. 1999;29(1):134–40.CrossRefPubMed Marx A, Gary Jr HE, Marston BJ, et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis. 1999;29(1):134–40.CrossRefPubMed
43.
go back to reference Zhu R, Song Q, Qian Y, et al. Virus profile in children with acute respiratory infections with various severities in Beijing, China. Chin Med J. 2014;127(21):3706–11.PubMed Zhu R, Song Q, Qian Y, et al. Virus profile in children with acute respiratory infections with various severities in Beijing, China. Chin Med J. 2014;127(21):3706–11.PubMed
44.
go back to reference Zwaans WAR, Mallia P, van Windena MEC, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease – a systematic review. J Clin Virol. 2014;61:181–8.CrossRefPubMed Zwaans WAR, Mallia P, van Windena MEC, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease – a systematic review. J Clin Virol. 2014;61:181–8.CrossRefPubMed
45.
go back to reference Djamin RS, Uzun S, Snelders E, et al. Occurrence of virus-induced COPD exacerbations during four seasons. Infect Dis. 2015;47(2):96–100.CrossRef Djamin RS, Uzun S, Snelders E, et al. Occurrence of virus-induced COPD exacerbations during four seasons. Infect Dis. 2015;47(2):96–100.CrossRef
46.
go back to reference Ford WR, Blair AE, Evans RL, et al. Human parainfluenza type 3 virus impairs the efficacy of glucocorticoids to limit allergy-induced pulmonary inflammation in guinea-pigs. Clin Sci (Lond). 2013;125(10):471–82.CrossRef Ford WR, Blair AE, Evans RL, et al. Human parainfluenza type 3 virus impairs the efficacy of glucocorticoids to limit allergy-induced pulmonary inflammation in guinea-pigs. Clin Sci (Lond). 2013;125(10):471–82.CrossRef
47.
go back to reference Konstantinidis I, Haehner A, Frasnelli J, et al. Post-infectious olfactory dysfunction exhibits a seasonal pattern. Rhinology. 2006;44(2):135–9.PubMed Konstantinidis I, Haehner A, Frasnelli J, et al. Post-infectious olfactory dysfunction exhibits a seasonal pattern. Rhinology. 2006;44(2):135–9.PubMed
48.
go back to reference Sugiura M, Aiba T, Mori J, et al. An epidemiological study of postviral olfactory disorder. Acta Otolaryngol Suppl. 1998;538:191–6.PubMed Sugiura M, Aiba T, Mori J, et al. An epidemiological study of postviral olfactory disorder. Acta Otolaryngol Suppl. 1998;538:191–6.PubMed
49.
go back to reference Wang JH, Kwon HJ, Jang YJ. Detection of parainfluenza virus 3 in turbinate epithelial cells of postviral olfactory dysfunction patients. Laryngoscope. 2007;117(8):1445–9.CrossRefPubMed Wang JH, Kwon HJ, Jang YJ. Detection of parainfluenza virus 3 in turbinate epithelial cells of postviral olfactory dysfunction patients. Laryngoscope. 2007;117(8):1445–9.CrossRefPubMed
50.
go back to reference Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):219–32.CrossRef Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):219–32.CrossRef
51.
go back to reference Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010;202(2):234–41.CrossRefPubMedPubMedCentral Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010;202(2):234–41.CrossRefPubMedPubMedCentral
53.
go back to reference Pessi A, Langella A, Capitò E, et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One. 2012;7(5):e36833.CrossRefPubMedPubMedCentral Pessi A, Langella A, Capitò E, et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One. 2012;7(5):e36833.CrossRefPubMedPubMedCentral
54.
go back to reference Crowe JE. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine. 1995;13(4):415–21.CrossRefPubMed Crowe JE. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine. 1995;13(4):415–21.CrossRefPubMed
55.
go back to reference Greenberg DP, Walker RE, Lee MS, et al. A bovineparainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. JInfect Dis. 2005;191(7):1116–22.CrossRef Greenberg DP, Walker RE, Lee MS, et al. A bovineparainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. JInfect Dis. 2005;191(7):1116–22.CrossRef
56.
go back to reference Karron RA, Makhene M, Gay K. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to-six-month old infants. Pediatr Infect Dis J. 1996;15:650–4.CrossRefPubMed Karron RA, Makhene M, Gay K. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two-to-six-month old infants. Pediatr Infect Dis J. 1996;15:650–4.CrossRefPubMed
57.
go back to reference Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines infants and young children. Vaccine. 2012;30(26):3975–81.CrossRefPubMed Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines infants and young children. Vaccine. 2012;30(26):3975–81.CrossRefPubMed
58.
go back to reference Gomez M, Mufson MA, Dubovsky F, et al. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratorysyncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009;28(7):655–8.CrossRefPubMed Gomez M, Mufson MA, Dubovsky F, et al. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratorysyncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009;28(7):655–8.CrossRefPubMed
59.
go back to reference Belshe RB, Newman FK, Tsai TF, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live atten-uated vaccine in healthy children 6–18 months old. J Infect Dis. 2004;189(3):462–70.CrossRefPubMed Belshe RB, Newman FK, Tsai TF, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live atten-uated vaccine in healthy children 6–18 months old. J Infect Dis. 2004;189(3):462–70.CrossRefPubMed
60.
go back to reference Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol. 1999;73(2):1374–81.PubMedPubMedCentral Skiadopoulos MH, Surman S, Tatem JM, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol. 1999;73(2):1374–81.PubMedPubMedCentral
62.
go back to reference Karron RA, Casey R, Thumar B, et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp 45 is well-tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J. 2011;30(10):e186–91.CrossRefPubMedPubMedCentral Karron RA, Casey R, Thumar B, et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp 45 is well-tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J. 2011;30(10):e186–91.CrossRefPubMedPubMedCentral
63.
go back to reference Englund JA, Karron RA, Cunningham CK, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.CrossRefPubMedPubMedCentral Englund JA, Karron RA, Cunningham CK, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.CrossRefPubMedPubMedCentral
64.
go back to reference Senchi K, Matsunaga S, Hasegawa H, et al. Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol. 2013;4:346.CrossRefPubMedPubMedCentral Senchi K, Matsunaga S, Hasegawa H, et al. Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. Front Microbiol. 2013;4:346.CrossRefPubMedPubMedCentral
65.
go back to reference Karron RA, San Mateo J, Thumar B, et al. Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. J Pediatric Infect Dis Soc. 2015;4(4):e143–6.CrossRefPubMed Karron RA, San Mateo J, Thumar B, et al. Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. J Pediatric Infect Dis Soc. 2015;4(4):e143–6.CrossRefPubMed
Metadata
Title
The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract
Authors
Malgorzata Pawełczyk
Marek Leszek Kowalski
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 3/2017
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-017-0685-2

Other articles of this Issue 3/2017

Current Allergy and Asthma Reports 3/2017 Go to the issue

Occupational Allergies (JA Poole, Section Editor)

Occupational Latex Allergy: the Current State of Affairs

Allergies and the Environment (M Hernandez, Section Editor)

A Review of Electronic Devices to Assess Inhaler Technique

Allergies and the Environment (M Hernandez, Section Editor)

Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence

Basic and Applied Science (I Lewkowich, Section Editor)

Mechanisms Driving Gender Differences in Asthma